title: Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C.
abstract: OBJECTIVE
  The risk of adverse drug interactions with interferon-alpha has been poorly assessed. The aim of our study was to establish whether administration of interferon-alpha at therapeutic doses in patients with chronic hepatitis C may have significant inhibitory effects on other drug metabolism. The study was focused on cytochromes P-450 1A2 and 3A, two major isoforms involved in the metabolism of numerous substrates.
  
  
  METHODS
  Eighteen patients with chronic active hepatitis C requiring an interferon-alpha treatment were studied. Cytochrome P-450 1A2 activity was determined on the basis of an in vivo caffeine metabolism study. Cytochrome P-450 3A activity was determined according to in vivo cortisol metabolism into 6-beta-hydroxycortisol. Both activities were determined 1 month before, at initiation and 1 month after interferon-alpha therapy (3 x 10(6) units, three times a week).
  
  
  RESULTS
  There were no significant differences in the caffeine index (CYP 1A2) and in the 6-beta-hydroxycortisol/free cortisol urinary ratio (CYP 3A) before and after alpha interferon treatment
  
  
  CONCLUSIONS
  Chronic administration of interferon-alpha at therapeutic doses does not change in vivo cytochrome P-450 1A2 and 3A activities. These results support the suggestion that drugs metabolized by these isoenzymes may be used together with interferon-alpha in patients with chronic hepatitis C without significant risks of drug interactions.
authors.affiliation: Service d'Hépatogastroentérologie, Hôpital Saint-Eloi, Montpellier, France.
authors.forename: G P
authors.initials: GP
authors.lastname: Pageaux
authors.forename: Y
authors.initials: Y
authors.lastname: le Bricquir
authors.forename: F
authors.initials: F
authors.lastname: Berthou
authors.forename: N
authors.initials: N
authors.lastname: Bressot
authors.forename: M C
authors.initials: MC
authors.lastname: Picot
authors.forename: F
authors.initials: F
authors.lastname: Blanc
authors.forename: H
authors.initials: H
authors.lastname: Michel
authors.forename: D
authors.initials: D
authors.lastname: Larrey
mesh_terms: D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D016898:Interferon-alpha / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D019388:Cytochrome P-450 CYP1A2; C106496:cytochrome P-450 CYP1A3 (rainbow trout)